The EDEM2 Knockout MES-OV Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population derived from the MES-OV human ovarian clear cell carcinoma cell line. This product features a targeted disruption of the EDEM2 gene, creating a heterogeneous pool of cells with diverse loss-of-function alleles. Such polyclonal populations avoid the clonal biases of single-cell-derived lines and provide a more representative model for studying EDEM2-dependent processes. The knockout primarily impacts the endoplasmic reticulum-associated degradation (ERAD) pathway and the unfolded protein response (UPR), both critical in cellular protein quality control.
The host MES-OV line was originally established from a patient diagnosed with ovarian clear cell carcinoma, a distinct epithelial ovarian cancer subtype associated with chemoresistance and an unfavorable clinical outcome. MES-OV cells maintain key malignant characteristics, including epithelial marker expression and the ability to form tumors in vivo. Employing this cell line for EDEM2 knockout allows direct investigation of glycoprotein quality control mechanisms within a disease-relevant context, where ER stress and the UPR are frequently upregulated and contribute to oncogenic progression.
EDEM2 encodes a mannosidase-like protein that recognizes terminally misfolded glycoproteins for ERAD. Its expression is upregulated by the UPR transcription factors spliced XBP1, ATF6, and ATF4, downstream of ER stress sensors. EDEM2 interacts with OS-9, XTP3-B, SEL1L, and HRD1 to facilitate retrotranslocation and ubiquitination of substrates before proteasomal degradation via VCP/p97. Loss of EDEM2 leads to accumulation of misfolded proteins, inducing ER stress and activation of BiP, CHOP, and IRE1.
In ovarian clear cell carcinoma, EDEM2 knockout enables study of how cancer cells depend on ERAD for proteotoxic stress management. High ER stress from rapid proliferation and the tumor microenvironment may render EDEM2 crucial for survival. EDEM2 disruption can impair this adaptive mechanism, potentially sensitizing cells to ER stress-inducing agents, thus offering a model to explore therapeutic vulnerabilities and the role of protein quality control in ovarian cancer progression.
Researchers can utilize these polyclonal knockout cells in a range of experimental approaches. Representative assays include Western blotting for EDEM2, BiP, CHOP, and IRE1; RT-qPCR for XBP1 splicing and ATF4 transcript levels; RNA-seq for global transcriptomic profiling; immunofluorescence to detect ER markers and ubiquitin conjugates; flow cytometry for apoptosis and cell cycle analysis; and proteasome activity assays. Co-immunoprecipitation experiments can further explore interactions with EDEM2 partners such as OS-9 and SEL1L. For additional information, please contact Ascent Research.
